Sergio Traversa, Relmada Therapeutics’ chief executive officer, bought 200,000 shares across two transactions priced from $4.10 to $4.18 per share. The purchases left him with 1,500,000 shares, giving investors a clear reference for the CEO’s reported post-transaction ownership in the company.
Key Highlights
- The purchases took place on September 9 and September 10, 2026.
- All transactions carried transaction code P.
- Sergio Traversa’s reported ownership was 1,500,000 shares after the transactions.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) Chief Executive Officer Sergio Traversa bought 200,000 shares across two transactions priced from $4.10 to $4.18 per share. The purchases left Traversa with 1,500,000 shares.
The transactions occurred on September 9 and September 10, 2026. The transactions carried code P. The disclosed prices ranged from $4.10 to $4.18 per share. Traversa made the purchases in his role as Relmada Therapeutics’ chief executive officer.
CEO Holding Reaches 1,500,000 Shares
Following the transactions, Traversa owned 1,500,000 shares. The reported ownership figure is the holding stated after both purchases were completed.
FAQs
Q: How many Relmada shares did Sergio Traversa buy?
A: Sergio Traversa purchased 200,000 Relmada Therapeutics shares across two transactions dated September 9 and September 10, 2026, at prices from $4.10 to $4.18 per share.
Q: What type of Relmada stock transactions were completed?
A: The filing identifies both transactions with SEC transaction code P. They covered 200,000 shares priced between $4.10 and $4.18 per share.
Q: How many RLMD shares did Sergio Traversa own afterward?
A: Following the two reported purchases, Sergio Traversa owned 1,500,000 shares of Relmada Therapeutics. The filing states this ownership figure after the transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.